 Aptorum Group Limited Nasdaq: APM Aptorum Group, a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, announces positive data and development in relation to its repurposed drug candidate, SACT-1, for the treatment of neuroblastoma, a rare type of childhood cancer that develops in infants and young children. Subject to completion of current validation studies, Aptorum Group plans to leverage the 505b2 pathway and submit an IND submission with the FDA for SACT-1 in H2 2020.1 